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Abstract 
During the last decade, several strategies have been developed to improve the detection 
sensitivity of in situ hybridization (ISH) by amplification of either target nucleic acid 
sequences prior to ISH (e.g., in situ PCR), or the detection signals after the hybridization 
procedures (signal amplification). Here we outline the principles of tyramide signal 
amplification using the catalyzed reporter deposition (CARD) technique, summarize 
applications as well as possible limitations of CARD ISH, and discuss some future direc- 
tions of in situ nucleic acid detection using this amplification strategy. 
Key Words: In situ hybridization; tyromide; signal amplification; mRNA; DNA; catalyzed 
reporter deposition; interphase cytogenetics. 
Department of Pathology 
University of Zurich, 
Schmelzbergstrasse 12, 
CH-8091 Zurich, Switzerland 
Address correspondence to 
Ernst J. M. Speel. Ph.D. 
Department of Pathology, 
University of Zurich, 
Schmelzbergstrasse 12, 
CH-8091 Zurich, Switzerland. 
E-mail: ernst-jom.speel@pty.usz.ch 
Endocrine Pathology, vol. 10, 
no. 3, 193-198, Fall 1999 
9 Copyright 1999 by Humana 
Press Inc. All rights of any 
nature whatsoever reserved. 
1046-3976/99/10:193-198/$11.50 
Introduction 
In situ hybridization (ISH) is now an 
established molecular tool in research and 
diagnostics and has significantly advanced 
the study ofgene structure and expression 
at the level of individual cells. Currently, 
the technique provides an optimal detec- 
tion sensitivity of approx 1 kb of target 
DNA in cell preparations using fluores- 
cence approaches in combination with 
charge-coupled device (CCD) recordings 
and image analysis [1]. The ultimate 
mRNA detection limit, however, is more 
difficult to determine but may reach the 
level of single mRNA molecules in the most 
optimal test systems [2]. For detection 
of nucleic acid sequences in routinely 
processed tissue sections of paraffin- 
embedded specimens, these sensitivities 
may not be reached. As a consequence, ISH 
detection limits on tissue sections are r ther 
in the range of 40 kb of target DNA and 
10-20 copies ofmRNA or viral DNA per 
cell [3-6]. 
In recent years, several strategies have 
been developed to improve the sensitivity 
oflSH. These include the use of increased 
absolute amounts of hybridized probes 
(cocktails of oligonucleotides or multiple 
cRNA probes) [7] and the amplification 
of either nucleic acid targets (target ampli- 
fication) [8,9] or of (immuno) cytochemi- 
cal detection signals (signal amplification) 
in situ [10,11]. 
In general, target amplification methods 
combine polymerase chain reaction 
(PCR) and ISH to visualize specific ampli- 
fied DNA and RNA sequences within cell 
and tissue preparations. Theoretically 
these in situ PCR techniques are straight- 
forward, but in practice they are hampered 
by several obstacles, such as low amplifi- 
cation efficiency (restricted sensitivity), 
poor reproducibility (restricted specific- 
ity), and difficulties in quantification of 
the results [12-15]. As a consequence, 
other approaches to increase the sensitiv- 
ity of ISH have been explored, of which 
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Fig. 1. Principles of CARD signal amplification for ISH. (A) Hybridization in situ with a hapten-labeled probe. (B) Application of a one-step 
(anti-hapten antibody conjugated to horseradish peroxidase; B~), two-step (anti-hapten antibody and a horseradish peroxidase labeled 
secondary antibody; B2), or three-step (avidin-biotin horseradish peroxidase complex; B3) probe detection system. (C) Production of haptenized 
tyramide radicals by horseradish peroxidase catalyzed CARD signal amplification. (D) Deposition of tyramide radicals to tyrosine moieties of 
proteins in situ in the vicinity of hybridization. Direct visualization of fluorochrome-labeled tyramides and indirect visualization of hapten- 
labeled tyramides with anti-hapten antibody or (strept)avidin conjugates labeled with fluorochromes or enzymes. 
the CARD signal amplification method 
appears to be the most promising. 
Principles of CARD Signal 
Amplification 
The method of CARD signal amplifi- 
cation has been developed by Bobrow et 
al. [16] for use in immuno-blotting and 
ELISA assays and is based on the deposi- 
tion of a large number of haptenized 
tyramide molecules promoted by peroxi- 
dase activity (Fig. 1). Tyramine is a phenolic 
compound and horseradish peroxidase 
(HRP) can catalyze the dimerization of 
such compounds when they are present at 
high concentrations probably by the gen- 
eration of free radical intermediates. If 
applied in lower concentrations, such as 
used in the signal amplification reaction, 
the probability of tyramine dimerization 
is reduced, whereas the binding of the 
highly reactive intermediates to elec- 
tron-rich moieties of proteins, uch as tyro- 
sine, at or near the site of the peroxidase 
binding site is favored. In this way, many 
hapten-labeled tyramine molecules (tyra- 
mides) can be deposited at the hybridiza- 
tion site in situ. Visualization of deposited 
tyramides can be performed either directly 
after the CARD reaction with fluorescence 
microscopy, if fluorochrome-labeled 
tyramides are used, or indirectly with either 
fluorescence or brightfield microscopy, if 
biotin, digoxigenin, di- or trinitrophenyl 
are used as haptens, which can act as fur- 
ther binding sites for anti-hapten antibod- 
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ies or (strept)avidin conjugates (in the case 
of biotinylated tyramides) [3]. Also fluo- 
rescein and rhodamin can be used as hap- 
tens, since specific antibodies against these 
fluorochromes are commercially available 
from several companies. 
Applications and Limitations of 
CARD Signal Amplification 
CARD signal amplification with bioti- 
nylated tyramides has been adapted for 
immunohistochemistry by Adams [17], 
allowing an increase in sensitivity of up to 
1000-fold when compared with conven- 
tional avidin biotinylated enzyme complex 
(ABC) procedures [17-21 ]. In these stud- 
ies, the amplification factor was assessed 
by determining the maximal dilution of the 
primary antibody leading still to identical 
staining results as compared with standard 
reactions. In most cases, however, the 
increase in sensitivity seems to be rather in 
the range of 50-100-fold, and sometimes 
even less. As a consequence of this vari- 
ability the optimal dilution for every pri- 
mary antibody needs to be determined. 
CARD signal amplification has also been 
applied to visualize antigens or incorpo- 
rated BrdU in fuorescence microscopy 
[22,23] or electron microscopy [24,25], 
and has further been used for double stain- 
ing with two unconjugated primary anti- 
sera raised in the same species [26]. 
Since 1995, CARD has further been 
implemented in detection procedures of 
both DNA and RNA ISH on cell prepara- 
tions and tissue sections. With signal 
amplification, the ISH sensitivity could be 
improved in the range of 2- to 100-fold, 
enabling the detection of up to three dif- 
ferent repetitive and single-copy (1-5 kb) 
DNA sequences in the same cell [22,27- 
30] as well as low copy viral RNA [31,32] 
and mRNA ranging from high to low 
abundancy in cell and tissue preparations 
[10,33-36]. 
As an example of the diagnostic poten- 
tial of CARD ISH, we have implemented 
CARD signal amplification for our diag- 
nostic nonradioactive oligonucleotide ISH 
procedure in order to increase the sensitiv- 
ity of the assay and to shorten its overall 
turnaround-time [10,33]. This approach 
allows, e.g., the detection of peptide hor- 
mone mRNA in tissue sections from rou- 
tinely fixed, paraffin-embedded surgical 
samples within one working day and makes 
the assay suitable for routine diagnostic 
purposes. Furthermore, it allows the use 
of diaminobenzidine (DAB) as a chro- 
mogen and, as a consequence, the applica- 
tion of conventional counterstains and the 
mounting of slides in xylene-based mount- 
ing solutions, making the procedure more 
acceptable toperform in a diagnostic setting. 
To date, most of the protocols till use 
biotinylated tyramides for the amplifica- 
tion step, which can easily be obtained 
commercially (e.g., NEN Life Science 
Products, Boston, MA and Dako, Glost- 
rup, Denmark) or synthesized in the labo- 
ratory [16,17,27,28,30,37]. However, 
similar to immunohistochemical proce- 
dures, the use of biotin is associated with 
significant disadvantages, pecially when 
working with tissue sections. Thus, in 
tissues with high amounts of endogenous 
biotin, such as liver or kidney, a low signal- 
to-noise ratio due to high background 
staining may be encountered. It is there- 
fore desirable to be able to rely on differently 
labeled tyramides, e.g., with digoxigenin, 
di- or trinitriphenyl [10,30,33], or fluo- 
rochromes [10,22,30,33,34], which is now 
possible. These tyramide conjugates can also 
be used in multiple-target ISH approaches 
[22,29,30] or the combination of imm- 
unohistochemistry and ISH with signal 
amplification. 
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Although the increase in ISH sensitivity 
by using CARD signal amplification is
obvious from the literature, speculation 
about he obtained amplification factor is 
difficult. Moreover, since the tyramide 
deposition reaction runs very quickly, 
minor differences in amplification reaction 
time may lead to variations in the final 
signal intensities. Nevertheless, an ampli- 
fication factor in the range of 5- to 10-fold, 
or possibly higher, together with preserva- 
tion of distinct localization of ISH signals 
seems to be a realistic indication for both 
DNA and mRNA ISH. 
Since with CARD signal amplification 
both specific and nonspecific (background) 
ISH signals will be amplified, it is essential 
that nonspecific probe binding and 
detection have to be avoided in order 
to successfully apply this procedure 
[22,30,35,36]. Therefore, we recommend 
that one should always optimize probe 
hybridization and cytochemical probe 
detection when applying CARD signal 
amplification i order to achieve discretely 
localized ISH signals of high intensity. In 
our hands, the number of cytochemical 
detection layers (e.g., one layer is sufficient 
for repetitive, centromeric DNA detection 
but minimal two layers are recommended 
for DNA targets of 40 kb), the dilution of 
detection conjugates (usually the first detec- 
tion layer can be diluted 2-10-fold further 
than in conventional detection systems), 
the tyramide concentration i  the CARD 
amplification buffer (usually concentra- 
tions in the range of 2-12 ~tM are used 
[30]), and the reaction time (usually 5-15 
min at room temperature or 37~ are the 
most important parameters toconsider. 
Conclusions 
CARD signal amplification using 
labeled tyramides i an easy-to-perform, 
fast, highly sensitive, and efficient proce- 
dure to increase the detection sensitivity 
of ISH and immunohistochemistry and
appears to become the method of choice 
for diagnostic laboratories. It will not only 
promote the detection of viral or mRNA 
but also facilitate the evaluation of chro- 
mosomal aberrations in cytological and 
histological specimens. Furthermore, it
might also help to advance the develop- 
ment of automated ISH spot-counting by 
computer-assisted image generation and 
analysis. The now available spectrum of 
probe labels, detection systems, and 
tyramide conjugates for CARD signal 
amplification will further improve the 
applicability and sensitivity oflSH as well 
as promote multiple-target nucleic acid 
detection in situ and procedures combin- 
ing ISH and immunophenotyping [38]. 
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